title: Synchrotron X-ray fluorescence microscopy of gallium in bladder tissue following gallium maltolate administration during urinary tract infection.
abstract: A mouse model of cystitis caused by uropathogenic Escherichia coli was used to study the distribution of gallium in bladder tissue following oral administration of gallium maltolate during urinary tract infection. The median concentration of gallium in homogenized bladder tissue from infected mice was 1.93 μg/g after daily administration of gallium maltolate for 5 days. Synchrotron X-ray fluorescence imaging and X-ray absorption spectroscopy of bladder sections confirmed that gallium arrived at the transitional epithelium, a potential site of uropathogenic E. coli infection. Gallium and iron were similarly but not identically distributed in the tissues, suggesting that at least some distribution mechanisms are not common between the two elements. The results of this study indicate that gallium maltolate may be a suitable candidate for further development as a novel antimicrobial therapy for urinary tract infections caused by uropathogenic E. coli.
authors.affiliation: Department of Veterinary Biomedical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
authors.forename: Katherine R
authors.initials: KR
authors.lastname: Ball
authors.forename: Francesca
authors.initials: F
authors.lastname: Sampieri
authors.forename: Manuel
authors.initials: M
authors.lastname: Chirino
authors.forename: Don L
authors.initials: DL
authors.lastname: Hamilton
authors.forename: Robert I R
authors.initials: RI
authors.lastname: Blyth
authors.forename: Tsun-Kong
authors.initials: TK
authors.lastname: Sham
authors.forename: Patricia M
authors.initials: PM
authors.lastname: Dowling
authors.forename: Julie
authors.initials: J
authors.lastname: Thompson
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D008856:Microscopy, Fluorescence; D009942:Organometallic Compounds / Q000493:pharmacokinetics* / Q000494:pharmacology; D011753:Pyrones / Q000493:pharmacokinetics* / Q000494:pharmacology; D017356:Synchrotrons; D001743:Urinary Bladder / Q000187:drug effects* / Q000382:microbiology / Q000473:pathology; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D056689:Uropathogenic Escherichia coli / Q000187:drug effects / Q000254:growth & development; D019459:Urothelium / Q000187:drug effects* / Q000382:microbiology / Q000473:pathology; D014965:X-Rays
chemical_list: D000900:Anti-Bacterial Agents; D009942:Organometallic Compounds; D011753:Pyrones; C512662:gallium maltolate